Find a TenderAwarded without competition
Published 19 Nov 2026, 09:39 GMT

Official UK procurement notice

Gene testing and reporting for Ovarian cancer specimens

Official notice

Authority: NHS Greater Glasgow and Clyde (NHS & healthcare)

ServicesAward procedure without prior publication of a call for competition
Awarded value£363,000published contract · exc. VAT
Awarded 12 Nov 2026no call for competition
Awarded to Myriad Genetics
Notice summaryFrom the published notice

NHS Greater Glasgow and Clyde, Laboratory Genetics requires an end-to-end diagnostic service for FFPE block processing, DNA based Homologous Repair Deficiency (HRD) and BRCA1 and BRCA2 gene testing and reporting for Ovarian cancer specimens. This service is required for approximately 200 tests per annum and the service must be available by 1st December 2026. The technical processing and laboratory reporting must be validated to ISO 15189 (2022) standards or equivalent and the underlying technology used must be clinically validated with demonstrable assessment against clinical outcomes. The service must have a robust trackability process to ensure that FFPE blocks are processed sensitively and returned to Laboratory Genetics NHS GGC.

What is being bought

Published requirement description

NHS Greater Glasgow and Clyde, Laboratory Genetics requires an end-to-end diagnostic service for FFPE block processing, DNA based Homologous Repair Deficiency (HRD) and BRCA1 and BRCA2 gene testing and reporting for Ovarian cancer specimens. This service is required for approximately 200 tests per annum and the service must be available by 1st December 2026.

CPV: Services provided by medical laboratories

Open work like this

This notice no longer takes bids · live search, filters set

The lotProcurement structure

single lot · no lot value published
Lot #1NHS Greater Glasgow and Clyde requires an end-to-end diagnostic service for FFPE block…

NHS Greater Glasgow and Clyde requires an end-to-end diagnostic service for FFPE block processing, DNA based Homologous Repair Deficiency (HRD) and BRCA1 and BRCA2 gene testing and reporting for Ovarian cancer specimens. The technical processing and laboratory reporting must be validated to ISO 15189 (2022) standards or equivalent and the underlying technology used must be clinically validated with demonstrable assessment against clinical outcomes.

The service must have a robust trackability process to ensure that FFPE blocks are processed sensitively and returned to Laboratory Genetics NHS GGC.

This service is required for approximately 200 tests per annum and the service must be available by 1st December 2026.

The provider must be able to meet NHS GGC boards Information Technology and Security and Information Governance frameworks by completion of Data Protection Impact Assessment (DPIA), and establishing a Data Processing Agreement (DPA) along with a Systems Security Policy (SSP) as applicable. All information governance, cyber-security and any contractual agreements must be established and in place by 01/12/2026 as the current HRD service, based within the UK, will cease to exist from 01/12/2026.

The supplier must be able to provide a fixed cost per test, between 01/12/2026-31/12/2027.

There are no Scottish Genomic Laboratories able to provide this test. We require a rapid solution to ensure that patients needing the HRD test can access the test and associated treatment pathways based on the test result. Not having a test available for this patient cohort will lead to significant patient harm and even early death. Additional information: Contract valid 01/12/2026 - 31/12/2027

Delivery: Scotland

Commercial outcome & contract awards

Published awards, contracts and bid statistics, not a forecast
Awards 1
Awarded value £363,0001 contract exc. VAT
Contracts signed 1latest 12 Nov 2026
Awarded toValueDateStatus
Myriad Genetics£363,000 †—Awarded

Contracts

  • Contract 109560-2026-1 · Myriad Genetics

    Signed
    12 Nov 2026
    Value
    £363,000
    Status
    active

Procedure terms & legal framework

From the official record · publisher note attached
Procedure method
Award procedure without prior publication of a call for competition
Legal basis
CELEX · 32014L0024 Public Contracts Regulations 2015 (Directive 2014/24/EU)
Procurement category
Services
Notice status
Awarded without competition
Procurement threshold
Unspecified in notice
Regulatory regime
Standard
Commercial structure
Stand-alone contract (no framework)
Competition type
Direct award (no call for competition)
GPA / WTO covered
Yes (GPA)
Recurring procurement
Unspecified in notice
First published
19 Nov 2026, 09:39 GMT
Last source update
19 Nov 2026, 09:39 GMT
FTS notice number
2026/S 000-109560
Classification (CPV)
Services provided by medical laboratories
Delivery area
Scotland (UKM82)
Official registry OCID
ocds-h6vhtk-07bf2e Find a Tender
Why no open competition
The procurement falls outside the scope of application of the directive
Published justification

NHSGGC will follow Regulation 33, (c)where (but only if it is strictly necessary) for reasons of extreme urgency brought about by events unforeseeable by the contracting authority, the time limits for open procedure, restricted procedure or competitive procedure with negotiation cannot be complied with.

NHS GGC were informed on 03/11/2026 that the current HRD service, based within the UK, will no longer be available beyond 01/12/2026.

NHS GGC require a rapid solution as this highly-specialist test cannot cease, to ensure that patients needing the HRD test can access the test and associated treatment pathways based on the test result.

Publisher note: NOTE: To register your interest in this notice and obtain any additional information please visit the Public Contracts Scotland Web Site at https://www.publiccontractsscotland.gov.uk/Search/Search_Switch.aspx?ID=848772. (SC Ref:848772)

Contracting authority & participating public bodies

NHS Greater Glasgow and Clyde

Contracting authorityNHS & healthcareBody governed by public lawHealth Procurement Department, Glasgow Royal Infirmary, 84 Castle Street, Glasgow, Scotland, G4 0SFContact email, phone

Dispute resolution & review bodies

  • Glasgow Sheriff CourtReview body Glasgow

Bidders & participating suppliers

1 commercial party on the notice
  • Myriad GeneticsAwarded supplier The Stanley Building, 7 Pancras Square, London, UK, N1C 4AG

Official documents & specifications

Official links; attachments are not copied

No document links were published on the notice.